Abcam, ab283662, Anti-LIFR antibody [EPR24651-109] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal LIFR antibody. Carrier free. Suitable for WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24651-109,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab283662 is the carrier-free version of
ab283651
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The leukemia inhibitory factor receptor also known as LIFR is a protein that plays an important role in cellular signaling. It has a mass of approximately 190-210 kDa and it is widely expressed in various tissues such as the liver muscle and bone. LIFR is a member of the interleukin 6 (IL-6) receptor family. The 'LIFR selector' refers to its ability to bind and select its specific ligand leukemia inhibitory factor (LIF) which initiates signal transduction processes. LIFR expression tends to be higher in developing tissues indicating its involvement during embryogenesis.
Biological function summary
The leukemia inhibitory factor receptor is involved in various cellular processes including differentiation proliferation and survival. When LIF binds to LIFR it forms a complex with gp130 another receptor protein which then activates downstream signaling pathways that regulate these cellular processes. This complex formation is an important component in the maintenance of stem cell pluripotency which is important in early development. The LIFR meaning in this context is essential for translating extracellular signals into cellular responses.
Pathways
The leukemia inhibitory factor receptor plays a critical role in the JAK/STAT signaling pathway. This pathway is significant for transmitting information received from extracellular chemical signals to the cell nucleus resulting in DNA transcription. LIFR closely interacts with other proteins like STAT3 and JAK1 which further propagate the signaling cascade initiated by LIF binding. Another pathway involving LIFR is the MAPK/ERK pathway a major pathway that influences cell growth and differentiation. These pathways highlight the interconnectivity of LIFR in regulating key cellular functions.
LIFR has been linked to cancer progression and osteoporosis. Abnormal LIFR signaling can lead to unchecked cellular proliferation contributing to tumorigenesis in various cancers such as liver and breast cancer. LIFR also interacts with proteins like gp130 and the aforementioned STAT3 in the cancerous context. In osteoporosis altered LIFR expression affects bone metabolism potentially leading to increased bone resorption and weakening. The role of LIFR in these diseases demonstrates its potential as a therapeutic target and its importance in maintaining normal tissue homeostasis.